MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-24-2026
AstraZeneca PLC EV - Enterprise Value 2011-2026 | AZN
Annual EV - Enterprise Value AstraZeneca PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.7 B | 56.1 B | 53.3 B | 141 B | 169 B | 159 B | 125 B | 120 B | 109 B | 123 B | 129 B | 113 B | 92.4 B | 94.5 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 169 B | 53.3 B | 110 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
1.47 B | $ 18.36 | -0.78 % | $ 2.7 B | USA |
 |
Amgen
AMGN
|
145 B | $ 343.69 | 0.53 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.02 B | $ 70.78 | 2.09 % | $ 9.47 B | USA |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
-15.2 M | $ 2.66 | 2.31 % | $ 16.7 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
395 M | $ 2.97 | 8.0 % | $ 167 M | China |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.14 | -0.95 % | $ 7.55 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
10.8 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Biogen
BIIB
|
28.3 B | $ 179.14 | -0.42 % | $ 26.1 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
725 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
486 M | $ 1.41 | -0.35 % | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
726 M | $ 223.85 | -1.0 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
3.22 B | $ 9.82 | 1.34 % | $ 1.59 B | Britain |
 |
BioNTech SE
BNTX
|
-6.64 B | $ 110.32 | -3.02 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-18.3 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.39 | 1.09 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
157 M | $ 1.72 | -1.71 % | $ 82 M | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 4.13 | 2.99 % | $ 8.99 B |  Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.72 B | $ 14.13 | 3.25 % | $ 4.37 B | USA |
 |
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
2.58 B | $ 6.69 | 1.6 % | $ 1.38 B | USA |
 |
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
2.59 B | $ 27.78 | 0.58 % | $ 2.29 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |